AETHLON MEDICAL INC — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Aethlon Medical (Parent, ~$5.7M market cap) agreed to merge with North Immunology (Company) in an all-stock transaction dated September 17, 2026. Company valued at $150M equity value plus proceeds from pre-closing financing. Exchange ratio determined by formula: Company Merger Shares / Company Outstanding Shares, where valuations and Parent Net Cash are calculated and subject to dispute resolution. Surviving entity becomes North Immunology, Inc.; Parent shareholders receive contingent value rights (CVRs) tied to future milestones.
Why this rating
Transformational reverse merger: $150M acquisition target is ~26x Aethlon's market cap ($5.7M). Business combination changes ownership, name, and control; massive capital raise ($175M minimum concurrent investment). Highly material to tiny public shell.
Tradability signal
NO TRADE
No trade: already up 30.0% on the news and the fade evidence is too weak. Similar past filings (5 in this cell) moved +0.00% in the called direction over 4 hrs; shrunk for sample size that's a +0.00% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $6.90 ▼ 21.62% | at our read · unknown $8.80 | +10 min · unknown $8.49 ▼ 3.56% | +30 min · unknown $7.90 ▼ 10.26% | +1 hr · unknown $7.00 ▼ 20.49% | +4 hrs · unknown $6.55 ▼ 25.64% |
The stock had already moved +27.58% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.